Latest Insite Vision Inc (INSV) Headlines
InSite Vision receives USD1m in royalties from the sale of Besivance
M2 - Wed Feb 05, 4:47AM CST
US-based ophthalmologic company InSite Vision Incorporated (Other OTC:INSV) stated on Tuesday that Besivance 2013 net sales has generated an additional USD1m milestone payment.
InSite Vision Announces Achievement of the $1 Million Milestone From the Sale of Besivance(R) Royalty
Business Wire - Tue Feb 04, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Edwards Lifesciences Lifted to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 5:26PM CST
On Dec 28, Zacks Investment Research upgraded medical device major, Edwards Lifesciences Corporation to a Zacks Rank #3 (Hold).
Genomic Health Remains Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 12:55PM CST
We reaffirm our long-term Neutral recommendation on Genomic Health following its third-quarter 2013 results.
Myriad Maintained at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 3:45PM CST
On Dec 23, we reaffirmed our long-term Neutral recommendation on Myriad Genetics Inc.
Affymetrix Reaches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 1:00PM CST
Shares of Affymetrix started escalating following its promising third quarter results on Oct 30.
InSite Vision Announces Positive Confirmatory Phase 3 Results for BromSite(TM) for the Reduction of Inflammation and Pain after Cataract Surgery
Business Wire - Wed Dec 18, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced top-line results from its recently completed confirmatory Phase 3 clinical trial of BromSite(TM) (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision's DuraSite(R) drug delivery technology.
InSite Vision to Host Research and Development Conference Call and Webcast on January 9, 2014
Business Wire - Wed Dec 18, 7:30AM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that the company will host a web-based meeting on Thursday, January 9,2014 at 10:00 a.m. PT / 1:00 p.m. ET to review the company's late-stage product development pipeline, recent Phase 3 clinical trial results and 2014 regulatory plans. Investors will be invited to ask questions following management's prepared remarks.
Surging Rank, Surging Stock: Why InSite Vision (INSV) is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 6:30AM CST
One company that should be on your radar is InSite Vision Incorporated. The stock of this company has seen its Zacks Rank surge over the past four weeks, moving from Hold to its current position as a Strong Buy.
Market Research: Blepharitis - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/xqzhc2/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H2 2013" report to their offering. Blepharitis - Pipeline Review, H2 2013, provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blepharitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blepharitis. Scope - A snapshot of the global therapeutic scenario for Blepharitis. - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Blepharitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Lux Biosciences, Inc. InSite Vision Incorporated Foamix Ltd. LABORATOIRES THEA Kala Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/xq...lepharitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Orexigen Therapeutics (OREX) Jumps: Stock Rises 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 26, 7:39AM CST
Orexigen Therapeutics, Inc. was a big mover last session as its shares rose over 9% on the day.
Curis, Inc. (CRIS) Soars: Stock Adds 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 26, 6:51AM CST
Curis, Inc. was a big mover last session as its shares surged around 12% on the day.
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 22, 7:39AM CST
Peregrine Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 6% on the day.
InSite Vision Reports Third Quarter 2013 Financial Results
Business Wire - Tue Nov 12, 3:03PM CST
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended September 30, 2013. Revenues for the third quarter of 2013 were $5.3 million compared to $12.1 million for the same period in 2012. Included in the third quarter of 2013 and 2012 were an additional $3.7 million and $9.3 million, respectively, in minimum royalty true-up payments from Merck on net sales of AzaSite. Net income for the third quarter of 2013 was $0.6 million, or less than $0.01 per share, compared to net income of $5.1 million, or $0.04 per share, in the third quarter of 2012.
InSite Vision Completes Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain Following Cataract Surgery
Business Wire - Thu Nov 07, 3:30PM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that the last patient has completed dosing and evaluation in the confirmatory Phase 3 clinical trial of BromSite(TM) (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision's DuraSite(R) drug delivery technology.
InSite Vision Announces Appeal by Sandoz Inc. of Court Judgment Upholding All AzaSite(R) Patents in Patent Infringement Lawsuit
Business Wire - Tue Nov 05, 3:36PM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Sandoz Inc. has filed an appeal of the court judgment that recently upheld the patents protecting AzaSite(R) (azithromycin 1% ophthalmic solution). The appeal was filed in the United States Court of Appeals for the Federal Circuit.
InSite Vision to Report Third Quarter 2013 Financial Results on November 12, 2013
Business Wire - Thu Oct 31, 7:30AM CDT
InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the third quarter ended September 30, 2013 on Tuesday, November 12, 2013.
OTC Signal Daily Stock Watch - InSite Vision (OTCQB: INSV)
WorldStockWire - Sun Oct 13, 11:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
New Jersey District Court sustains InSite Vision's AzaSite patents
M2 - Wed Oct 09, 5:34AM CDT
InSite Vision Incorporated (OTCBB: INSV), a company that develops products to treat a growing range of common eye problems, has announced that the US District Court for the District of New Jersey sustained all four of the patents protecting AzaSite, an azithromycin one percent ophthalmic solution, in a patent infringement lawsuit against Sandoz, it was reported yesterday.
InSite Vision receives USD1m in royalties from the sale of Besivance
M2 - Wed Feb 05, 4:47AM CST
US-based ophthalmologic company InSite Vision Incorporated (Other OTC:INSV) stated on Tuesday that Besivance 2013 net sales has generated an additional USD1m milestone payment.
InSite Vision Announces Achievement of the $1 Million Milestone From the Sale of Besivance(R) Royalty
Business Wire - Tue Feb 04, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Edwards Lifesciences Lifted to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 5:26PM CST
On Dec 28, Zacks Investment Research upgraded medical device major, Edwards Lifesciences Corporation to a Zacks Rank #3 (Hold).
Genomic Health Remains Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 12:55PM CST
We reaffirm our long-term Neutral recommendation on Genomic Health following its third-quarter 2013 results.
Myriad Maintained at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 3:45PM CST
On Dec 23, we reaffirmed our long-term Neutral recommendation on Myriad Genetics Inc.
Affymetrix Reaches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 1:00PM CST
Shares of Affymetrix started escalating following its promising third quarter results on Oct 30.
InSite Vision Announces Positive Confirmatory Phase 3 Results for BromSite(TM) for the Reduction of Inflammation and Pain after Cataract Surgery
Business Wire - Wed Dec 18, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced top-line results from its recently completed confirmatory Phase 3 clinical trial of BromSite(TM) (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision's DuraSite(R) drug delivery technology.
InSite Vision to Host Research and Development Conference Call and Webcast on January 9, 2014
Business Wire - Wed Dec 18, 7:30AM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that the company will host a web-based meeting on Thursday, January 9,2014 at 10:00 a.m. PT / 1:00 p.m. ET to review the company's late-stage product development pipeline, recent Phase 3 clinical trial results and 2014 regulatory plans. Investors will be invited to ask questions following management's prepared remarks.
Surging Rank, Surging Stock: Why InSite Vision (INSV) is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 6:30AM CST
One company that should be on your radar is InSite Vision Incorporated. The stock of this company has seen its Zacks Rank surge over the past four weeks, moving from Hold to its current position as a Strong Buy.
Market Research: Blepharitis - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/xqzhc2/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H2 2013" report to their offering. Blepharitis - Pipeline Review, H2 2013, provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blepharitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blepharitis. Scope - A snapshot of the global therapeutic scenario for Blepharitis. - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Blepharitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Lux Biosciences, Inc. InSite Vision Incorporated Foamix Ltd. LABORATOIRES THEA Kala Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/xq...lepharitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Orexigen Therapeutics (OREX) Jumps: Stock Rises 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 26, 7:39AM CST
Orexigen Therapeutics, Inc. was a big mover last session as its shares rose over 9% on the day.
Curis, Inc. (CRIS) Soars: Stock Adds 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 26, 6:51AM CST
Curis, Inc. was a big mover last session as its shares surged around 12% on the day.
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 22, 7:39AM CST
Peregrine Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 6% on the day.
InSite Vision Reports Third Quarter 2013 Financial Results
Business Wire - Tue Nov 12, 3:03PM CST
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended September 30, 2013. Revenues for the third quarter of 2013 were $5.3 million compared to $12.1 million for the same period in 2012. Included in the third quarter of 2013 and 2012 were an additional $3.7 million and $9.3 million, respectively, in minimum royalty true-up payments from Merck on net sales of AzaSite. Net income for the third quarter of 2013 was $0.6 million, or less than $0.01 per share, compared to net income of $5.1 million, or $0.04 per share, in the third quarter of 2012.
InSite Vision Completes Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain Following Cataract Surgery
Business Wire - Thu Nov 07, 3:30PM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that the last patient has completed dosing and evaluation in the confirmatory Phase 3 clinical trial of BromSite(TM) (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision's DuraSite(R) drug delivery technology.
InSite Vision Announces Appeal by Sandoz Inc. of Court Judgment Upholding All AzaSite(R) Patents in Patent Infringement Lawsuit
Business Wire - Tue Nov 05, 3:36PM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Sandoz Inc. has filed an appeal of the court judgment that recently upheld the patents protecting AzaSite(R) (azithromycin 1% ophthalmic solution). The appeal was filed in the United States Court of Appeals for the Federal Circuit.
InSite Vision to Report Third Quarter 2013 Financial Results on November 12, 2013
Business Wire - Thu Oct 31, 7:30AM CDT
InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the third quarter ended September 30, 2013 on Tuesday, November 12, 2013.
OTC Signal Daily Stock Watch - InSite Vision (OTCQB: INSV)
WorldStockWire - Sun Oct 13, 11:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
New Jersey District Court sustains InSite Vision's AzaSite patents
M2 - Wed Oct 09, 5:34AM CDT
InSite Vision Incorporated (OTCBB: INSV), a company that develops products to treat a growing range of common eye problems, has announced that the US District Court for the District of New Jersey sustained all four of the patents protecting AzaSite, an azithromycin one percent ophthalmic solution, in a patent infringement lawsuit against Sandoz, it was reported yesterday.
